Mast cell number, phenotype, and function in human pulmonary arterial hypertension [0.03%]
人肺动脉高压的肥大细胞数量、表型和功能
Samar Farha,Jacqueline Sharp,Kewal Asosingh et al.
Samar Farha et al.
A proliferation of mast cells around the small pulmonary blood vessels and the alveolar septae has been noted in models of pulmonary hypertension, and in plexiform lesions of pulmonary arterial hypertension (PAH) in patients. Here, we hypot...
Adriano R Tonelli,Metin Aytekin,Ariel E Feldstein et al.
Adriano R Tonelli et al.
Evidence suggests that leptin is involved in relevant processes in the cardiovascular system. Low serum leptin levels have been associated with increased cardiovascular events and mortality in patients with coronary artery, diabetes, or chr...
Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming [0.03%]
骨形态生成蛋白受体2突变的人肺内皮细胞的代谢组分析发现了广泛的代谢重构现象
Joshua P Fessel,Rizwan Hamid,Bryan M Wittmann et al.
Joshua P Fessel et al.
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease of the lung vasculature for which the molecular etiologies are unclear. Specific metabolic alterations have been identified in animal models and in PAH patients, thoug...
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets [0.03%]
血小板凝血醇合成酶抑制剂Furegrelate对预防新生猪肺动脉高压的作用
Dinesh K Hirenallur-S,Neil D Detweiler,Steven T Haworth et al.
Dinesh K Hirenallur-S et al.
The development of pulmonary arterial hypertension (PAH) in pediatric patients has been linked to the production of the arachidonic acid metabolite, thromboxane A(2) (TxA(2)). The present study evaluated the therapeutic effect of furegrelat...
Group V phospholipase A(2) increases pulmonary endothelial permeability through direct hydrolysis of the cell membrane [0.03%]
Ⅴ组磷脂酶A(2)通过直接水解细胞膜增加肺内皮通透性
Nilda M Muñoz,Anjali Desai,Lucille N Meliton et al.
Nilda M Muñoz et al.
Acute lung injury (ALI) is characterized by inflammatory disruption of the alveolar-vascular barrier, resulting in severe respiratory compromise. Inhibition of the intercellular messenger protein, Group V phospholipase A(2) (gVPLA(2)), bloc...
Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension [0.03%]
间充质干细胞介导的支气管肺发育不良和相关性肺高压的逆转作用
Georg Hansmann,Angeles Fernandez-Gonzalez,Muhammad Aslam et al.
Georg Hansmann et al.
Clinical trials have failed to demonstrate an effective preventative or therapeutic strategy for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disease in preterm infants frequently complicated by pulmonary hypertension (PH...
Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction [0.03%]
左心舒张功能障碍相关肺动脉高压的诊断与治疗
Vinicio A de Jesus Perez,Francois Haddad,Roham T Zamanian
Vinicio A de Jesus Perez
Pulmonary hypertension (PH) is commonly seen in patients who present with left ventricular diastolic dysfunction (LVDD) and is considered a marker of poor prognosis. While PH in this setting is thought to result from pulmonary venous conges...
Evaluation of patients with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy [0.03%]
慢性血栓性肺动脉高压患者肺内膜剥脱术适应证的选择及危险因素的评估
William R Auger,Kim M Kerr,Nick H Kim et al.
William R Auger et al.
Pulmonary hypertension as a result of chronic thromboembolic disease (CTEPH) is potentially curable with pulmonary endarterectomy surgery. Consequently, correctly diagnosing patients with this type of pulmonary hypertension and evaluating t...
Severe pulmonary hypertension: The role of metabolic and endocrine disorders [0.03%]
严重肺动脉高压与代谢及内分泌异常的关系
Harm J Bogaard,Aysar Al Husseini,Laszlo Farkas et al.
Harm J Bogaard et al.
Pulmonary arterial hypertension (PAH) is a multi-factorial condition and the underlying pulmonary vascular disease is shaped by the combined action of genetic, epigenetic and immune-related factors. Whether and how gender, obesity and the m...
Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension [0.03%]
长期反复吸入一氧化氮治疗肺动脉高压的临床观点
Robyn J Barst,Richard Channick,Dunbar Ivy et al.
Robyn J Barst et al.
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease of the pulmonary vasculature with a high morbidity and mortality. Its pathobiology involves at least three interacting pathways - prostacyclin (PGI(2)), endothelin, and...